Parabilis Medicines PBLS 深 沪
等待开盘 10-09 09:30:00 美东时间
28.405
-0.415
-1.44%
华盛通- 最 高28.86
- 今 开28.42
- 成交量 91.65万股
- 最 低 26.14
- 昨 收 28.82
- 总市值 350.90万
- 52周最高 42.485
- 市盈率 静 --
- 换手率 0.74%
- 52周最低 24.51
- 委 比 -90.48%
- 总股本 0.00亿
- 历史最高 42.485
- 量 比 1.73
- 振 幅 9.44%
- 历史最低 24.51
- 每 手 1
- 风险率 4.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
MeiraGTx Holdings plc announced the appointment of Alan M. Sebulsky to its Board of Directors. With over 40 years of experience in healthcare and biopharmaceutical investment, Sebulsky has led a $2 billion biopharmaceutical portfolio at Adage Capital Management and founded Apothecary Capital. He currently serves on the board of Parabilis Medicines and previously on boards of Jazz Pharmaceuticals and Arrow International. MeiraGTx, a clinical-stage...
09-23 12:00
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining around 400 points on Thursday. Shares of Vicor Corp (NASDAQ:VICR) rose sharply after the company announced it granted a non-exclusive license to a new OEM licensee with the right to procure Vertical Power Delivery modules by its patents from...
09-17 23:58
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler, a seasoned oncology expert with over 30 years of experience at Johnson & Johnson, will also continue his role as a scientific advisor. His extensive background in clinical development and regulatory approvals is expected to significantly benefit Parabilis as it advances its lead drug, zolucatetide, and expands its pipeline of innovativ...
08-25 11:00
Parabilis Medicines Q2 EPS $(2.32) Misses $(0.08) Estimate, Sales $148.000K Miss $25.000M Estimate
Parabilis Medicines (NASDAQ:PBLS) reported quarterly losses of $(2.32) per share which missed the analyst consensus estimate of $(0.08) by 2800 percent. This is a 89.59 percent increase over losses of $(22.28) per share from the same period last year. The company reported quarterly sales of $148.000...
08-13 19:29
最大赢家不是AI！生物科技成美股IPO“黑马” 平均回报率达55% 大幅跑赢整体市场
今年美国首次公开募股(IPO)市场的最大赢家并非人工智能(AI)企业，而是生物科技板块。受行业基本面改善、大型药企并购活跃以及资本持续流入推动，生物科技IPO表...
07-21 23:23
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-18 18:30
美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
07-07 11:34
B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45
B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.
07-06 18:29
美股周涨跌榜 | 生物制药股NUVL涨超35%，获葛兰素史克高额溢价收购；超微电脑跌超26%，70亿美元的股权融资引市场忧虑
生物制药股NUVL涨超35%，获葛兰素史克高额溢价收购；支付公司Payoneer涨超33%，获加拿大支付公司Nuvei收购；超微电脑跌超26%，70亿美元的股权融资引市场忧虑>>
06-13 09:46
